Megestrol acetate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for megestrol acetate and what is the scope of patent protection?
Megestrol acetate
is the generic ingredient in three branded drugs marketed by Bristol Myers Squibb, Endo Pharms Inc, Akorn, Breckenridge, Hikma, Pharm Assoc, Strides Pharma, Teva Pharms, Twi Pharms, Wockhardt Bio Ag, Barr, Teva, and Usl Pharma, and is included in eighteen NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Megestrol acetate has thirty-six patent family members in nineteen countries.
There are seventeen drug master file entries for megestrol acetate. Fourteen suppliers are listed for this compound.
Summary for megestrol acetate
International Patents: | 36 |
US Patents: | 5 |
Tradenames: | 3 |
Applicants: | 13 |
NDAs: | 18 |
Drug Master File Entries: | 17 |
Finished Product Suppliers / Packagers: | 14 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 73 |
Patent Applications: | 7,223 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for megestrol acetate |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for megestrol acetate |
What excipients (inactive ingredients) are in megestrol acetate? | megestrol acetate excipients list |
DailyMed Link: | megestrol acetate at DailyMed |
Recent Clinical Trials for megestrol acetate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 1/Phase 2 |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2 |
Sunnybrook Health Sciences Centre | Phase 1 |
Pharmacology for megestrol acetate
Drug Class | Progestin |
Medical Subject Heading (MeSH) Categories for megestrol acetate
Paragraph IV (Patent) Challenges for MEGESTROL ACETATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MEGACE ES | Oral Suspension | megestrol acetate | 125 mg/mL | 021778 | 1 | 2011-04-27 |
US Patents and Regulatory Information for megestrol acetate
Expired US Patents for megestrol acetate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol Myers Squibb | MEGACE | megestrol acetate | SUSPENSION;ORAL | 020264-001 | Sep 10, 1993 | See Plans and Pricing | See Plans and Pricing |
Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | See Plans and Pricing | See Plans and Pricing |
Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for megestrol acetate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2008546796 | See Plans and Pricing | |
Mexico | 2008000396 | FORMULACIONES DE MEGESTROL EN NANOPARTICULA. (NANOPARTICULATE MEGESTROL FORMULATIONS.) | See Plans and Pricing |
Denmark | 1494649 | See Plans and Pricing | |
Israel | 188322 | See Plans and Pricing | |
Canada | 2481390 | PREPARATIONS DE MEGESTROL NANOPARTICULAIRES (NANOPARTICULATE MEGESTROL FORMULATIONS) | See Plans and Pricing |
Australia | 2003230885 | NANOPARTICULATE MEGESTROL FORMULATIONS | See Plans and Pricing |
Slovenia | 1494649 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.